Tenon Medical, Inc. - What You Need to Know

Thinking about investing in Tenon Medical (TNON)? Before you commit your hard-earned money, let’s break down what this company does in plain English.

Disclaimer: I am an AI, not a financial advisor. Investing in companies like this is highly speculative and risky. Always do your own research or talk to a professional before investing.

1. What does this company actually do?

Tenon Medical makes surgical tools designed to treat chronic lower back pain, specifically focusing on the sacroiliac (SI) joint, which connects your spine to your pelvis.

They currently offer two primary systems:

• The Catamaran System: Their original tool uses a titanium implant to stabilize the joint and help bones fuse naturally.
• The SImmetry+ System: Acquired in August 2025, this tool is designed to prepare joint surfaces to encourage more effective fusion than stabilization alone.

Tenon’s business model relies on selling these surgical kits and specialized tools to hospitals and surgery centers.

2. What is the market opportunity?

Tenon is targeting a significant clinical need. They estimate that over 30 million American adults suffer from chronic lower back pain, with 15% to 30% of those cases involving the SI joint. Currently, only a small fraction (5% to 7%) of these patients undergo surgery. Tenon believes existing procedures are overly complex and hopes to capture more of this market by offering surgeons a faster, simpler alternative.

3. What is happening right now?

As of June 2026, Tenon is raising capital by selling shares and warrants for $0.60 per unit.

• The "Warrants": These give you the right to buy more shares later at a set price. However, these warrants are not listed on any major stock exchange. Because there is no public market for them, they can be very difficult to sell. If the stock price never rises above the warrant’s exercise price, the warrants will effectively become worthless.

4. The "Fine Print" Risks

Investing in an early-stage company like this involves significant hurdles that you should be aware of:

• Immediate Dilution: This is a major factor. You are paying $0.60 per share, but the company’s "net tangible book value"—the actual value of its assets minus its debts—is only about $0.11 per share. This means the accounting value of your investment is significantly lower than the price you are paying at the time of purchase.
• The Nasdaq "Warning": Tenon is currently failing to meet Nasdaq’s listing requirements, specifically regarding the minimum $1.00 share price and required stockholders' equity. If they do not resolve these issues by August 24, 2026, they could be delisted. Being kicked off the Nasdaq would make the stock much harder to trade and could cause the price to drop further.
• Management Flexibility: The company has "broad discretion" on how to spend the money they raise. They may use it for daily operations, research, or other corporate needs. As an investor, you will have no say in these spending decisions.
• No Dividends: The company has never paid a cash dividend and does not plan to start. Any potential profit depends entirely on the stock price increasing, which is never guaranteed.

5. The Bottom Line

Tenon is an "Emerging Growth Company," meaning they provide less financial transparency than larger, established firms. Between the risk of being delisted, the lack of a market for warrants, and the immediate dilution of your investment, this is a high-risk scenario.

Final thought: The low share price and the need for constant capital raises suggest the company is struggling to meet basic exchange requirements and maintain operations. This is a speculative investment; only invest money you are fully prepared to lose.